R. Scott Huennekens Net Worth

The estimated Net Worth of R Scott Huennekens is at least $20.4 Million dollars as of 3 June 2022. Mr. Huennekens owns over 60,000 units of Nuvasive Inc stock worth over $20,173,483 and over the last 10 years he sold NUVA stock worth over $34,800. In addition, he makes $230,057 as Independent Director at Nuvasive Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Huennekens NUVA stock SEC Form 4 insiders trading

R has made over 2 trades of the Nuvasive Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 60,000 units of NUVA stock worth $34,800 on 3 June 2022.

The largest trade he's ever made was selling 60,000 units of Nuvasive Inc stock on 3 June 2022 worth over $34,800. On average, R trades about 2,557 units every 47 days since 2015. As of 3 June 2022 he still owns at least 507,509 units of Nuvasive Inc stock.

You can see the complete history of Mr. Huennekens stock trades at the bottom of the page.

R. Scott Huennekens biography

R. Scott Huennekens serves as Independent Director of the Company. Mr. Huennekens most recently served as the President, Chief Executive Officer and Chairman of the Board of Verb Surgical, a start-up company formed by Google and Johnson & Johnson to develop an advanced digital surgery platform, from August 2015 to December 2018. Prior to joining Verb Surgical, Mr. Huennekens was the President, Chief Executive Officer and a member of the Board of Directors of Volcano Corporation, a medical technology company focused on diagnostic and therapeutic solutions for coronary and peripheral artery disease, from 2002 until Volcano was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. Huennekens served as the President and Chief Executive Officer of Digirad Corporation, a diagnostic imaging solutions provider. Mr. Huennekens brings to our Board medical device leadership experience and strategic insight, as well as significant knowledge and experience in robotics, data analytics and advanced surgical technologies.

What is the salary of R Huennekens?

As the Independent Director of Nuvasive Inc, the total compensation of R Huennekens at Nuvasive Inc is $230,057. There are 11 executives at Nuvasive Inc getting paid more, with J. Christopher Barry having the highest compensation of $5,425,440.

How old is R Huennekens?

R Huennekens is 55, he's been the Independent Director of Nuvasive Inc since 2018. There are 6 older and 13 younger executives at Nuvasive Inc. The oldest executive at Nuvasive Inc is Donald Rosenberg, 69, who is the Independent Director.

What's R Huennekens's mailing address?

R's mailing address filed with the SEC is C/O ENVISTA HOLDINGS CORPORATION, 200 S. KRAEMER BLVD., BLDG. E, BREA, CA, 92821.

Insiders trading at Nuvasive Inc

Over the last 21 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair, and Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.

What does Nuvasive Inc do?

nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through

Complete history of Mr. Huennekens stock trades at Bellerophon Therapeutics Inc, Nuvasive Inc, ViewRay, Envista Corp, and Acutus Medical

Nuvasive Inc executives and stock owners

Nuvasive Inc executives and other stock owners filed with the SEC include:

• J. Christopher Barry,
  Chief Executive Officer, Director
• J. Christopher Barry,
  CEO & Director
• Nathaniel Sisitsky,
  Senior Vice President, General Counsel, Corporate Secretary
• Matthew K. Harbaugh,
  Exec. VP & CFO
• Gregory Lucier,
  Chairman of the Board
• Nathaniel B. Sisitsky Esq.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Lucas Vitale,
  Sr. VP & Chief HR Officer
• Donald Rosenberg,
  Independent Director
• Daniel Wolterman,
  Independent Director
• Vickie Capps,
  Independent Director
• Leslie Norwalk,
  Independent Director
• R. Scott Huennekens,
  Independent Director
• Robert Friel,
  Independent Director
• John DeFord,
  Independent Director
• Suzanne Hatcher,
  Vice President, Internal & External Affairs
• Dale Wolf,
  Senior Vice President - Global Operations
• Massimo Calafiore,
  Executive Vice President - Global Business Units
• Brent Boucher,
  Executive Vice President - Global Commercial
• Lucas Vitale,
  Chief Human Resource Officer
• Matthew Harbaugh,
  Executive Vice President, Chief Financial Officer
• Marc Rosenbaum,
  VP, Corp. Controller & Chief Accounting Officer
• Michael Farrington,
  VP of Corp. Marketing, Brand & Communication
• Juliet C. Cunningham,
  VP of Investor Relations
• Ryan Donahoe,
  Chief Technology Officer
• Dale A. Wolf,
  Sr. VP of Global Operations
• Lisa Pecora,
  VP & Head of Global Commercial Fin.
• Frank Middeke,
  Managing Director of DACH
• Sean Freeman,
  Sr. VP of Strategy & Corp. Devel.
• Johnson Lai,
  Chief Information Officer
• Jereme M Sylvain,
  Chief Accounting Officer
• Jack R Blair,
  Director
• Peter Michael Leddy,
  Director
• Edmund J Roschak,
  CEO, NuVasive Spec. Orthopedic
• Dan Wolterman,
  Director
• Michael D Ohalleran,
  Director
• Lesley H Howe,
  Director
• Peter C Farrell,
  Director
• Joan Stafslien,
  EVP and General Counsel
• Quentin S. Blackford,
  CFO and CAO
• Cox Carol,
  EVP Strategy, Corp Dev
• Tyler Lipschultz,
  EVP, Biologics
• Andrew C. Morton,
  SVP, CHRO
• Matthew Link,
  President
• Rajesh Asarpota,
  CFO
• Paul Mc Clintock,
  President, U.S. Commercial
• Stephen Rozow,
  EVP, Global Process
• Jeffrey P Rydin,
  Senior V.P., U.S. Sales
• Jason Hannon,
  VP, Legal Affairs & Secretary
• Patrick Miles,
  Senior VP, Marketing
• Kevin C Oboyle,
  CFO and Executive VP
• James C Blair,
  Director
• James J Skinner,
  VP,Strategic Sales Development
• Jonathan Spangler,
  VP & Chief Patent Counsel
• G Bryan Cornwall,
  VP, Research & Development
• Hansen A Yuan,
  Director
• Arda Minocherhomjee,
  Director
• Blair Capital Management Vi...,
  
• Perkins Caufield & Byers Vi...,
  10% owner
• Joseph Lacob,
  Director
• G Rogan Fry,
  Sr. V. P., Corp. Development
• Viii Associates Lp Kpcb,
  10% owner
• Life Sciences Zaibatsu Fund...,
  10% owner
• Iv Associates Lp Dp,
  10% owner
• Jesse I Treu,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Brian H Dovey,
  10% owner
• Vii Associates Lp Kpcb,
  10% owner
• De Depot Et Placement Du Qu...,
  10% owner
• Management Partners Iv Lpen...,
  
• Partners Iv Lp Domain,
  10% owner
• Viii Founders Fund L P Kpcb,
  10% owner
• Russell Powers,
  Exec. VP Sales Int'l Ops
• Eileen M More,
  Director
• Keith Valentine,
  President
• Alexis V Lukianov,
  CEO and Chairman
• Michael E Paolucci,
  Exec. V.P., Global HR
• Craig E Hunsaker,
  SVP, Global Human Resources
• Richard Iii Treharne,
  Director
• Michael Lambert,
  CFO and Executive VP
• Robert J Hunt,
  Director
• Siddhartha Kadia,
  Director
• Amy Belt Raimundo,
  Director
• Michael Farrington,
  SVP, People and Culture
• Marc W. Rosenbaum,
  Chief Accounting Officer